А new drug in the complex therapy of diabetes mellitus. Post-registration experience in patients with type 1 and type 2 diabetes mellitus

Diabetes mellitus (DM), due to its high incidence and prevalence, presents an urgent problem for the scientific community, which requires new ways of treating and preventing complications. Existing hypoglycemic treatment approaches do not always contribute to the achievement of glycaemic targets. Objective . Study of Subetta-based therapy for patients with DM 1 and DM 2 in real-life clinical practice. Materials and methods . The program involved 71 patients with DM 1 and 289 patients with DM 2, HbA1c ≥ 7.0%, who took Subetta in combination therapy of diabetes. The duration of the program was 12 weeks. The laboratory examination included the determination of the level of HbA1c, fasting plasma glucose. Results . The administration of Subetta in complex therapy of DM 1 and DM 2 led to a significant reduction in HbA1c from 9.2 ± 1.85 to 8.13 ± 1.29 mmol/L and from 8.62 ± 1.54 to 7.49 ± 1.1 mmol/L, respectively (p<0.0001), reduction of fasting blood glucose from 9.33 to 7.65 mmol/l and from 9.25 to 7.08 mmol/l, respectively (p<0.0001). The effectiveness of therapy is highly appreciated by patients and physicians. The use of Subetta was not accompanied by the development of hypoglycemia and other adverse effects. Conclusion . In real-life clinical practice, use of new locally developed antidiabetic drug Subetta demonstrated a significant decrease of HbA1c and fasting blood glucose, with no episodes of hypoglycemia in patients with DM 1 and DM 2.